What's breaking now, across thousands of outlets.
Though barzolvolimab displayed what one analyst described as the best efficacy results to date against chronic skin hives, treatment was also associated with two life-threatening anaphylaxis cases.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.
Type 1 diabetes isn't an overnight attack against the body's ability to make insulin. It can be a sustained campaign over years that relentlessly targets insulin-producing cells in the pancreas.
Long-term research finds most children recovered from the effects of the pandemic.
(MedPage Today) -- Cardiologists Ronald Karlsberg, MD, and Venkatesh Murthy, MD, PhD, are among the new appointees to the U.S. Preventive Services Task Force (USPSTF).
Viking Therapeutics is developing VK2735, a GLP-1/GIP drug that could compete with Eli Lilly’s Zepbound. Its stock is soaring.
Viking Therapeutics is developing VK2735, a GLP-1/GIP drug that could compete with Eli Lilly’s Zepbound. Its stock is soaring.
Katie Rosier began drinking at 12. She got sober 32 years later, after DUIs, serious health issues, and time in a homeless shelter.
